Landscape Capital Management
CTMX icon

Landscape Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Landscape Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$256K Hold
94,240
– – 0.02% 521
2026
Q2 		$353K Hold
94,240
– – 0.02% 532
2026
Q1 		$443K Buy
+94,240
New +$478K 0.03% 522
2017
Q2 		– Sell
-70,943
Closed -$1.22M – 344
2017
Q1 		$1.22M Buy
+70,943
New +$934K 0.12% 154

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Peak Financial Advisors
Peak Financial Advisors Denver, Colorado $232M AUM 12.16% 1-Year Est. Return

Landscape Capital Management's CTMX Position: Q3 2026 in Review

Landscape Capital Management held its CytomX Therapeutics (CTMX) position steady in Q3 2026 at 94,240 shares worth $256K. The position accounts for 0.02% of the portfolio, ranked #521.

Landscape Capital Management first reported a position in CTMX in Q1 2017 and has held it in 4 quarters since. The position peaked at $1.22M in Q1 2017. 69 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.

  • Landscape Capital Management held 94,240 shares of CytomX Therapeutics worth $256K as of Q3 2026.
  • Landscape Capital Management left its CytomX Therapeutics share count unchanged in Q3 2026.
  • CytomX Therapeutics made up 0.02% of Landscape Capital Management's portfolio in Q3 2026, its #521 holding.
  • Landscape Capital Management first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 4 quarters since.
  • Landscape Capital Management's CytomX Therapeutics position peaked at $1.22M in Q1 2017.
  • 69 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.

Based on Landscape Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.